

## **HIV-Associated Lipodystrophy Study** (A Growth Hormone Releasing Factor Analog)

**Theratechnologies - Protocol TH9507:** A 52-Week Study (Comprised of a 26-Week Main Study Followed by a 26-Week Randomized Withdrawal Period) Designed for HIV-Positive Volunteers Who Have Evidence of Excess Abdominal Fat and Have Been Taking Antiretroviral Medications for At Least 8 Weeks Prior to Study Entry.

**Purpose:** The purpose of this clinical study is to confirm the findings of an earlier study, which indicated that TH9507 may reduce abdominal fat accumulation while improving total cholesterol/HDL ratio and TG levels. The study will also explore duration of effects on treatment and its long-term safety.

**About the study:** In the main study phase, volunteers will be randomly assigned to one of two groups (TH9507 or placebo). This main study will compare the use of the study drug TH9507 with a placebo after 26 weeks. The 52-week trial is designed to offer active treatment to all patients for at least 26 weeks.

### **Requirements:**

- HIV-positive adult ages 18 to 65 years inclusive
- Documentation of HIV infection
- Evidence of excess of abdominal fat accumulation
- Taking antiretroviral medications for 8 weeks prior to study entry

### **Study Location:**

Orange County Center for Special Immunology  
11190 Warner Avenue, Suite 411  
Fountain Valley, CA 92708  
Tel: 714-751-5800/Fax: 714-751-5860  
Contact our Research Dept. at ext. 26